Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
NCT03630055 · Ottawa Heart Institute Research Corporation · PHASE3 · terminated · last registry update 2026-05-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Assessment for futility” | – | Registry record, Ottawa Heart Institute Research Corporation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F10 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Results posted on the registry: University of Maryland, Baltimore, Kcentra + Frozen Plasma Product, Human (NCT03341156)
- 2026-11-10Also stopped (terminated): University of Maryland, Baltimore, Kcentra + Frozen Plasma Product, Human (NCT03341156)
- 2026-11-09Phase 3 first posted: Pfizer, marstacimab (NCT07923981)
- 2026-11-09Results posted on the registry: Octapharma, a drug against F10 (NCT03320603)
- 2026-11-06Also stopped (withdrawn): Emory University, Emicizumab + FEIBA (NCT04563520)
- 2026-11-05Also stopped (withdrawn): Kedrion S.p.A., Coagadex(R) (NCT06963216)
- 2026-10-21Also stopped (terminated): University Health Network, Toronto, Fibrinogen + PCC + Frozen Plasma (NCT04534751)
- 2026-10-05Also stopped (terminated): Pfizer, PF-06838435 (formerly SPK-9001) (NCT03307980)
- 2026-09-25Phase 3 first posted: Texas Cardiac Arrhythmia Research Foundation, Half-Dose of novel OAC + Low-dose ASA (NCT07840365)
- 2026-09-24Results posted on the registry: Ottawa Hospital Research Institute, Apixaban + Rivaroxaban (NCT02559856)
- 2026-08-21Phase 3 first posted: Unity Health Toronto, Eliquis (NCT07779746)
- 2026-08-14Results posted on the registry: Pfizer, PF-06741086 (NCT03938792)
- 2026-08-05Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran + Aspirin (NCT07746882)
- 2026-07-31Results posted on the registry: Spur Therapeutics, verbrinacogene setparvovec (NCT05164471)
- 2026-07-31Also stopped (terminated): Spur Therapeutics, verbrinacogene setparvovec (NCT05164471)
- 2026-07-24Also stopped (terminated): AstraZeneca, Ceralasertib + Drug X (NCT06929260)
- 2026-07-24Phase 3 first posted: University College, London, Apixaban 2.5 mg twice daily + Placebo (NCT07726693)
- 2026-07-17Phase 3 first posted: University of Arizona, Apixaban + Warfarin (NCT07709780)
- 2026-06-25Also stopped (terminated): Octapharma, Octaplex (NCT04867837)
- 2026-06-24Results posted on the registry: SHI Jia, Prothrombin Complex Concentrate, Human + Fresh Frozen Plasma (NCT04244981)
- 2026-06-24Also stopped (terminated): SHI Jia, Prothrombin Complex Concentrate, Human + Fresh Frozen Plasma (NCT04244981)
- 2026-06-24Results posted on the registry: Ottawa Hospital Research Institute, Apixaban + Rivaroxaban (NCT03266783)
- 2026-06-04Phase 3 first posted: Regeneron Pharmaceuticals, REGN7508 + Apixaban (NCT07626411)
- 2026-05-19Results posted on the registry: Massachusetts General Hospital, Rivaroxaban + Warfarin (NCT03702582)
- 2026-04-24Results posted on the registry: Chiayi Christian Hospital, Rivaroxaban 10 MG (NCT05449327)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision